Background: It is well known that full segmentary resection can be performed using oncoplastic surgery (OPS) techniques, and the anatomic resection of the ductal system is possible. Therefore, the efficacy and safety of OPS should be investigated in the treatment of ductal carcinoma in situ (DCIS). Patients and Methods: Patients who were diagnosed as pure DCIS and underwent surgical treatment and follow-up were retrospectively evaluated. Patients who underwent OPS and conventional breast-conserving surgery (BCS) were included in the study. The number of patients who required an intervention after the surgery and had a relapse during the follow-up period was determined in both groups. Results: There were 45 patients in the OPS group and 138 patients in the BCS group. The mean tumor size was larger in patients in the OPS group (36 ± 12 mm vs. 24 ± 8 mm, p = 0.02). Six (12.7%) patients were reoperated in the OPS group. Of these, 4 were re-excisions and 2 were mastectomies. In this group, breast conservation was possible in 45 (95.7%) patients. Thirty-nine (27%) patients were reoperated in the BCS group. Of these, 23 were re-excisions, and 16 were mastectomies. In this group, breast conservation was possible in 126 (88.7%) patients (p = 0.02). There was no significant difference between the groups in terms of 5-year cumulative local recurrence rates. While the 5-year local recurrence-free survival rate was 93.3% in the OPS group, it was 90.8% in the BCS group. Conclusion: This study provided evidence that OPS can be used safely in the surgical treatment of DCIS by reducing re-excision and completion mastectomy rates compared to BCS.

1.
Weigel
S
,
Khil
L
,
Hense
HW
,
Decker
T
,
Wellmann
J
,
Heidrich
J
, et al.
Detection Rates of Ductal Carcinoma in Situ with Biennial Digital Mammography Screening: Radiologic Findings Support Pathologic Model of Tumor Progression
.
Radiology
.
2018
Feb
;
286
(
2
):
424
32
.
[PubMed]
0033-8419
2.
Tang
P
,
Hajdu
SI
,
Lyman
GH
.
Ductal carcinoma in situ: a review of recent advances
.
Curr Opin Obstet Gynecol
.
2007
Feb
;
19
(
1
):
63
7
.
[PubMed]
1040-872X
3.
Love
SM
,
Barsky
SH
.
Breast-duct endoscopy to study stages of cancerous breast disease
.
Lancet
.
1996
Oct
;
348
(
9033
):
997
9
.
[PubMed]
0140-6736
4.
Silverstein
MJ
,
Lagios
MD
,
Groshen
S
,
Waisman
JR
,
Lewinsky
BS
,
Martino
S
, et al.
The influence of margin width on local control of ductal carcinoma in situ of the breast
.
N Engl J Med
.
1999
May
;
340
(
19
):
1455
61
.
[PubMed]
0028-4793
5.
Jeevan
R
,
Cromwell
DA
,
Trivella
M
,
Lawrence
G
,
Kearins
O
,
Pereira
J
, et al.
Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics
.
BMJ
.
2012
Jul
;
345
jul12 2
:
e4505
.
[PubMed]
0959-8138
6.
Weber
WP
,
Soysal
SD
,
El-Tamer
M
,
Sacchini
V
,
Knauer
M
,
Tausch
C
, et al.
First international consensus conference on standardization of oncoplastic breast conserving surgery
.
Breast Cancer Res Treat
.
2017
Aug
;
165
(
1
):
139
49
.
[PubMed]
0167-6806
7.
McCulley
SJ
,
Durani
P
,
Macmillan
RD
.
Therapeutic mammaplasty for centrally located breast tumors
.
Plast Reconstr Surg
.
2006
Feb
;
117
(
2
):
366
73
.
[PubMed]
0032-1052
8.
Ernster
VL
,
Ballard-Barbash
R
,
Barlow
WE
,
Zheng
Y
,
Weaver
DL
,
Cutter
G
, et al.
Detection of ductal carcinoma in situ in women undergoing screening mammography
.
J Natl Cancer Inst
.
2002
Oct
;
94
(
20
):
1546
54
.
[PubMed]
0027-8874
9.
Faverly
DR
,
Burgers
L
,
Bult
P
,
Holland
R
.
Three dimensional imaging of mammary ductal carcinoma in situ: clinical implications
.
Semin Diagn Pathol
.
1994
Aug
;
11
(
3
):
193
8
.
[PubMed]
0740-2570
10.
van la Parra
RF
,
Clough
KB
,
Lejalle-Alaeddine
C
,
Poulet
B
,
Sarfati
I
,
Nos
C
.
Oncoplastic Level 2 Mammoplasty for Large DCIS: 5-Year Results
.
Ann Surg Oncol
.
2019
Aug
;
26
(
8
):
2459
65
.
[PubMed]
1068-9265
11.
Correa
C
,
McGale
P
,
Taylor
C
,
Wang
Y
,
Clarke
M
,
Davies
C
, et al.;
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
.
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
.
J Natl Cancer Inst Monogr
.
2010
;
2010
(
41
):
162
77
.
[PubMed]
1052-6773
12.
Cochrane
RA
,
Valasiadou
P
,
Wilson
AR
,
Al-Ghazal
SK
,
Macmillan
RD
.
Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised
.
Br J Surg
.
2003
Dec
;
90
(
12
):
1505
9
.
[PubMed]
0007-1323
13.
Losken
A
,
Elwood
ET
,
Styblo
TM
,
Bostwick
J
 3rd
.
The role of reduction mammaplasty in reconstructing partial mastectomy defects
.
Plast Reconstr Surg
.
2002
Mar
;
109
(
3
):
968
75
.
[PubMed]
0032-1052
14.
Morrow
M
,
Van Zee
KJ
,
Solin
LJ
,
Houssami
N
,
Chavez-MacGregor
M
,
Harris
JR
, et al.
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ
.
Ann Surg Oncol
.
2016
Nov
;
23
(
12
):
3801
10
.
[PubMed]
1068-9265
15.
Coates
AS
,
Winer
EP
,
Goldhirsch
A
,
Gelber
RD
,
Gnant
M
,
Piccart-Gebhart
M
, et al.;
Panel Members
.
Tailoringtherapies—improvingthemanagement of earlybreast cancer: StGallenInternationalExpertConsensus on thePrimaryTherapy of EarlyBreastCancer2015
.
Ann Oncol
.
2015
Aug
;
26
(
8
):
1533
46
.
[PubMed]
0923-7534
16.
Melstrom
LG
,
Melstrom
KA
,
Wang
EC
,
Pilewskie
M
,
Winchester
DJ
.
Ductal carcinoma in situ: size and resection volume predict margin status
.
Am J Clin Oncol
.
2010
Oct
;
33
(
5
):
438
42
.
[PubMed]
0277-3732
17.
King
TA
,
Sakr
R
,
Patil
S
,
Gurevich
I
,
Stempel
M
,
Sampson
M
, et al.
Clinical management factors contribute to the decision for contralateral prophylactic mastectomy
.
J Clin Oncol
.
2011
Jun
;
29
(
16
):
2158
64
.
[PubMed]
0732-183X
18.
Szynglarewicz
B
,
Maciejczyk
A
,
Forgacz
J
,
Matkowski
R
.
Breast segmentectomy with rotation mammoplasty as an oncoplastic approach to extensive ductal carcinoma in situ
.
World J Surg Oncol
.
2016
Mar
;
14
(
1
):
72
.
[PubMed]
1477-7819
19.
Tadros
AB
,
Smith
BD
,
Shen
Y
,
Lin
H
,
Krishnamurthy
S
,
Lucci
A
, et al.
Ductalcarcinoma in situandmargins[{LT}]2 mm: contemporaryoutcomeswithbreastconservation
.
Ann Surg
.
2019
Jan
;
269
(
1
):
150
7
.
[PubMed]
0003-4932
20.
Song
HM
,
Styblo
TM
,
Carlson
GW
,
Losken
A
.
The use of oncoplastic reduction techniques to reconstruct partial mastectomy defects in women with ductal carcinoma in situ
.
Breast J
.
2010
Mar-Apr
;
16
(
2
):
141
6
.
[PubMed]
1075-122X
21.
De Lorenzi
F
,
Di Bella
J
,
Maisonneuve
P
,
Rotmensz
N
,
Corso
G
,
Orecchia
R
, et al.
Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis
.
Eur J Surg Oncol
.
2018
Jul
;
44
(
7
):
957
62
.
[PubMed]
0748-7983
22.
Clough
KB
,
van la Parra
RF
,
Thygesen
HH
,
Levy
E
,
Russ
E
,
Halabi
NM
, et al.
Long-termResultsAfterOncoplasticSurgeryforBreastCancer: A 10-year Follow-up
.
Ann Surg
.
2018
Jul
;
268
(
1
):
165
71
.
[PubMed]
0003-4932
23.
Eaton
BR
,
Losken
A
,
Okwan-Duodu
D
,
Schuster
DM
,
Switchenko
JM
,
Mister
D
, et al.
Local recurrence patterns in breast cancer patients treated with oncoplastic reduction mammaplasty and radiotherapy
.
Ann Surg Oncol
.
2014
Jan
;
21
(
1
):
93
9
.
[PubMed]
1068-9265
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.